• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Synthes $21.3 billion buyout reveals a tale of two suitors

Synthes $21.3 billion buyout reveals a tale of two suitors

July 13, 2011 By MassDevice staff

Johnson & Johnson
Synthes

The $21.3 billion marriage between Synthes and Johnson & Johnson (NYSE:JNJ) nearly wasn’t so, background documents filed with the U.S. Securities and Exchange Commission show.

A second suitor composed of a consortium of three private equity firms courted Synthes with an all-cash deal that nearly won the Swiss orthopedics specialist’s heart.

Regulatory filings released last week expose new details about how one of med-tech’s largest mergers since before the ill-fated $27 billion Boston Scientific/Guidant deal of 2006 went down. Unlike the Boston Scientific deal, where JNJ was outbid by a competitor, this time the New Brunswick, N.J. conglomerate found itself facing a three-headed private equity monster.

Further, when combined with the fresh $6.3 billion acquisition of Kinetic Concepts Inc. (NYSE:KCI) by a private equity firm and two Canadian pension funds, the acquisition reveals a renewed focus by buyout firms on the medical device industry.

Citing "a backdrop of significant changes to the regulatory, reimbursement, pricing and tax environments driven by healthcare reform and the weak economic environment that had reduced the growth prospects of Synthes and its industry," Synthes decided to test the waters in April 2010 by offering its hand to nine strategic partners and six private equity firms.

JNJ was the only strategic partner to make an offer, and JNJ officials proposed between CHF 145 and CHF 150 per share for Synthes stock, which comes to about $154.91 and $160.26 per share using historical currency exchange rates. Synthes stock was going for about CHF 122.70 and CHF 131.00 at the time, which translates to about $131.09 and $134.00.

Johnson & Johnson was ranked #2 on the MassDevice Big 100 list of the world’s largest medical device companies.

About 60 percent of the purchase was to be made in JNJ common stock and the rest in cash, according to the filing.

Meanwhile, a slew of private equity firms formed a consortium and offered their own bouquet of CHF 151 ($161.32) in cash in exchange for the Swish device giant’s hand.

Synthes was understandably torn. SEC filings show that the board of directors met several times to discuss the pros and cons of each offer, and even considered maintaining the status quo and remaining and independent company.

While staying single presented opportunities to focus on growth and dividends, it also meant exposure to a gloomy regulatory and fiscal climate. Saying yes to JNJ looked like a more stable option, even if its offer was lower than that of the consortium, since JNJ clearly had the capital to take the deal to the finish line. But it also meant accepting most of the payment in stock, which means a fluctuating final purchase price and value to stockholders.

Synthes also mulled over the private equity firms’ proposal. That deal likely meant less regulatory scrutiny and would probably close sooner than an acquisition by a strategic partner, but there was significant risk involved with the consortium’s ability to put together the cash to close the deal. The consortium had also posed an ultimatum in their offer: a substantial portion of Synthes board chairman Hansjörg Wyss’ equity in Synthes had to be transferred to the post-merger company.

The looming pressure of a stressed market and unsteady regulatory future pushed the company toward JNJ – but not before it upped its price to CHF 160 per share ($170.94). After some back-and-forth and due diligence reviews, the companies decided on CHF 159 per share ($169.87), with 65 percent in the form of JNJ stock and 35 percent in cash.

On April 25, 2011, the Synthes board of directors unanimously voted that the JNJ merger was a go, and on April 26 the companies took the plunge and executed the $21.3 billion merger agreement, issuing joint press releases prior to the opening of the Swiss financial markets on April 27.

Filed Under: Business/Financial News, Mergers & Acquisitions, News Well Tagged With: depuysynthes, Johnson and Johnson

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy